Papel de los biomarcadores en el cáncer urotelial

8 / 27

Vuky, J et al. ASCO 2018
stroma predicts benefit to
pembrolizumab in bladder
cancer
1L pembrolizumab in cisplatin-ineligible unresectable or metastatic urothelial
cancer: KEYNOTE-052